Internal biological mechanisms, rather than external exposures, drive these cancers
For generations, oral cancer carried a familiar face — the smoker, the drinker, the virus. But science has now named something quieter and more intimate: a subtype of oral cancer born not from external vice but from the body's own aging machinery, its immune defenses, and the invisible microbial world living within the mouth. Researchers analyzing nearly 350 tumors have drawn a boundary between what we long assumed and what is actually happening in a growing number of patients — younger, often female, and without a single traditional risk factor to explain their diagnosis.
- A rising tide of oral cancers in people who never smoked, never drank heavily, and tested negative for HPV has left clinicians without answers — and patients without a clear story.
- Analysis of 347 tumor samples exposed two entirely distinct cancer clusters bearing no trace of environmental carcinogens, driven instead by age-related mutations and the body's own APOBEC immune-editing process.
- Bacterial material found embedded within these tumors points to the oral microbiome as a possible co-conspirator, complicating the picture from a simple internal malfunction into a dynamic between aging, immunity, and microbial life.
- These NIRF tumors have learned to hide — their immune evasion features blunt the checkpoint therapies that work elsewhere, demanding a different therapeutic strategy entirely.
- The APOBEC mutational signature that defines many of these cancers may also be their weakness, suggesting targeted DNA damage response therapies could exploit what standard treatments cannot.
For decades, oral cancer had a clear origin story: cigarettes, alcohol, the human papillomavirus. But that story has been quietly unraveling. A growing number of patients — younger individuals and women in particular — are receiving diagnoses with none of those risk factors in their history. Their tumors have no obvious culprit. This mounting mystery drove Dr. Jiri Zavadil and his team at the International Agency for Research on Cancer to ask a harder question: what, exactly, is driving these cancers?
Drawing on data from The Cancer Genome Atlas, the researchers analyzed 347 tumor samples — 253 from the oral cavity and 94 from the larynx as a smoking-related reference point. They mapped the mutational signatures within each tumor, reading the damage like forensic evidence to determine not just that something had gone wrong, but how. Four distinct clusters emerged. Two confirmed the old story, bearing the unmistakable fingerprints of tobacco and alcohol. The other two did not. These NIRF — No Identified Risk Factor — tumors showed no environmental carcinogen signatures at all. What they carried instead were the marks of aging and APOBEC-mediated damage, a process generated by the body's own immune machinery.
The deeper the team looked, the more complex the picture became. These tumors showed activation of antimicrobial pathways and contained bacterial material within their tissue, suggesting the oral microbiome was not a passive bystander but a possible participant in the cancer's development. It was not infection in any classical sense — more a slow, intricate entanglement between cellular aging, immune response, and the microbial ecosystem of the mouth.
The clinical stakes are real. NIRF tumors have developed immune evasion strategies that blunt the checkpoint therapies effective against other cancers. Yet their APOBEC-driven mutational profile may expose a different vulnerability — sensitivity to therapies targeting DNA damage response pathways. Published in the International Journal of Oral Science in April 2026, the study does more than name a new subtype. It establishes that these cancers are a distinct biological entity with their own drivers and their own weaknesses — and that treating them well will require looking inward, toward the body's own processes, rather than searching for an external cause that was never there.
For decades, doctors knew what caused most oral cancers: cigarettes, alcohol, the human papillomavirus. A man who smoked for forty years developed a tumor in his mouth—the chain was clear. But something has shifted. More and more people without any of these risk factors are being diagnosed with oral squamous cell carcinoma, particularly younger patients and women. Their tumors have no obvious culprit, no smoking history to point to, no viral infection to blame. This growing mystery prompted researchers to ask a harder question: if traditional carcinogens aren't driving these cancers, what is?
Dr. Jiri Zavadil at the International Agency for Research on Cancer and his team set out to decode this puzzle. They pulled data from The Cancer Genome Atlas and analyzed 347 tumor samples—253 from the oral cavity and 94 from the larynx, the latter serving as a smoking-related control group. Using advanced genomic techniques, they mapped the mutational signatures within each tumor, looking for the fingerprints of whatever process had damaged the DNA. Mutational signatures are like crime scene evidence: they reveal not just that damage occurred, but how it happened, what kind of force caused it.
The analysis revealed four distinct clusters of tumors. Two matched the old story perfectly—they bore the hallmarks of smoking and alcohol exposure, with characteristic mutation patterns like SBS4 and SBS16. But the other two clusters told a different tale. These tumors, which the researchers called NIRF (No Identified Risk Factor) oral cancers, showed no trace of environmental carcinogens at all. Instead, they were dominated by signatures of aging and APOBEC-mediated damage, a process driven by the body's own immune system. The mutations were internal, self-inflicted in a sense—the result of the passage of time and the body's own cellular machinery gone awry.
What made this discovery even more intriguing was what the researchers found when they looked deeper into the biology of these NIRF tumors. The cancer cells showed activation of antimicrobial pathways and keratinization responses, and when the team examined the tumors under the microscope, they found bacterial components embedded within them. This suggested that the oral microbiome—the community of microbes living in the mouth—might be playing a role in driving these cancers. It was not a simple story of infection, but rather a complex interplay between the body's aging processes, its immune responses, and the microbial ecosystem it harbors.
The clinical implications are significant. NIRF tumors showed features of immune evasion, meaning they had evolved ways to hide from the body's immune system and evade checkpoint therapies that have worked well against other cancers. But they also showed vulnerability in a different direction: the APOBEC-driven mutations that characterized many of these tumors suggested they might be sensitive to therapies targeting DNA damage response pathways. This opens a door to precision medicine—the idea that treatment could be tailored not to broad categories of cancer, but to the specific molecular drivers of each individual tumor.
The study, published in the International Journal of Oral Science in April 2026, fundamentally reshapes how researchers and clinicians think about oral cancer. It establishes that cancers arising without traditional risk factors are not simply mysteries waiting to be solved by finding a hidden exposure. They are a distinct disease entity, with their own biology, their own drivers, their own vulnerabilities. For patients diagnosed with these tumors, and for the doctors treating them, this distinction matters. It means the search for answers can move beyond the usual suspects—smoking, alcohol, HPV—and toward the internal processes and microbial influences that may actually be at work. It means future treatments might be designed not to poison the body broadly, but to exploit the specific weaknesses of these particular cancers.
Citações Notáveis
We aimed to uncover the molecular mechanisms driving these cancers and to determine whether they represent a distinct subtype with unique biological characteristics.— Dr. Jiri Zavadil, International Agency for Research on Cancer
Internal biological mechanisms, rather than external exposures, play a key role in NIRF oral cancer development.— Prof. François Virard, Cancer Research Center of Lyon
A Conversa do Hearth Outra perspectiva sobre a história
So these NIRF cancers—they're just cancers that happen to people who don't smoke or drink. But that doesn't make them a new disease, does it?
Not exactly. The point is that they're driven by fundamentally different mechanisms. A smoking-related cancer and a NIRF cancer might look similar under a microscope, but at the molecular level they're almost different diseases. One is caused by external carcinogens, the other by aging and the body's own immune processes.
And the microbiome angle—how confident are the researchers that bacteria are actually causing these cancers?
They found bacterial components in the tumors and saw activation of antimicrobial pathways, but they're careful not to claim causation. It's more likely that the microbiome is part of the ecosystem where these cancers develop, not necessarily the primary driver. The aging and APOBEC mutations seem to be doing the heavy lifting.
Why does it matter that NIRF tumors show immune evasion?
Because it means the immunotherapies that have revolutionized cancer treatment—checkpoint inhibitors—might not work as well against these tumors. The cancer has already figured out how to hide from the immune system. But that same vulnerability to APOBEC-driven mutations opens a different therapeutic window.
So you're saying these patients might need completely different treatments than someone with a smoking-related oral cancer?
Exactly. That's the promise of precision medicine. Instead of treating all oral cancers the same way, you could match the treatment to the tumor's molecular profile. A NIRF patient might benefit from DNA damage response therapies that would be useless against a smoking-related cancer.
What happens next? Do we have these targeted therapies ready?
Not yet. This study is foundational—it identifies the problem and points toward solutions. The next phase is developing and testing therapies that exploit these specific vulnerabilities. It's a roadmap, not a finished product.